FDA Votes to Strengthen Warnings on Ortho-Evra Patch
Washington, DC: A post-marketing report released in October by the Food and Drug Administration (FDA) on the safety of new generation contraceptives reportedly states that the Ortho Evra Patch from Johnson & Johnson's Janssen division, and the norelgestromin/estradiol vaginal ring, are associated with an increased risk for venous thromboembolic events (VTE), compared with contraceptives containing lower doses of estrogen. The Ortho Evra Patch and the ring both contain higher levels of estrogen compared with older or second generation birth control pills. Ortho Evra Legal Help If you or a loved one have suffered injury in this case, please click the link below and your complaint will be sent to a drugs & medical lawyer who may evaluate your claim at no cost or obligation.
ADD YOUR COMMENT ON THIS STORYClick to learn more about LawyersandSettlements.com |
|